Literature DB >> 16731926

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

Nancy A Wilson1, Jason Reed, Gnankang S Napoe, Shari Piaskowski, Andy Szymanski, Jessica Furlott, Edna J Gonzalez, Levi J Yant, Nicholas J Maness, Gemma E May, Taeko Soma, Matthew R Reynolds, Eva Rakasz, Richard Rudersdorf, Adrian B McDermott, David H O'Connor, Thomas C Friedrich, David B Allison, Amit Patki, Louis J Picker, Dennis R Burton, Jing Lin, Lingyi Huang, Deepa Patel, Gwendolyn Heindecker, Jiang Fan, Michael Citron, Melanie Horton, Fubao Wang, Xiaoping Liang, John W Shiver, Danilo R Casimiro, David I Watkins.   

Abstract

The goal of an AIDS vaccine regimen designed to induce cellular immune responses should be to reduce the viral set point and preserve memory CD4 lymphocytes. Here we investigated whether vaccine-induced cellular immunity in the absence of any Env-specific antibodies can control viral replication following multiple low-dose challenges with the highly pathogenic SIVmac239 isolate. Eight Mamu-A*01-positive Indian rhesus macaques were vaccinated with simian immunodeficiency virus (SIV) gag, tat, rev, and nef using a DNA prime-adenovirus boost strategy. Peak viremia (P = 0.007) and the chronic phase set point (P = 0.0192) were significantly decreased in the vaccinated cohort, out to 1 year postinfection. Loss of CD4(+) memory populations was also ameliorated in vaccinated animals. Interestingly, only one of the eight vaccinees developed Env-specific neutralizing antibodies after infection. The control observed was significantly improved over that observed in animals vaccinated with SIV gag only. Vaccine-induced cellular immune responses can, therefore, exert a measure of control over replication of the AIDS virus in the complete absence of neutralizing antibody and give us hope that a vaccine designed to induce cellular immune responses might control viral replication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731926      PMCID: PMC1472612          DOI: 10.1128/JVI.00171-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

3.  Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes.

Authors:  Zdenek Hel; Wen-Po Tsai; Elzbieta Tryniszewska; Janos Nacsa; Phillip D Markham; Mark G Lewis; George N Pavlakis; Barbara K Felber; Jim Tartaglia; Genoveffa Franchini
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

4.  The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Authors:  Levi J Yant; Thomas C Friedrich; Randall C Johnson; Gemma E May; Nicholas J Maness; Alissa M Enz; Jeffrey D Lifson; David H O'Connor; Mary Carrington; David I Watkins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Authors:  Danilo R Casimiro; Fubao Wang; William A Schleif; Xiaoping Liang; Zhi-Qiang Zhang; Timothy W Tobery; Mary-Ellen Davies; Adrian B McDermott; David H O'Connor; Arthur Fridman; Ansu Bagchi; Lynda G Tussey; Andrew J Bett; Adam C Finnefrock; Tong-ming Fu; Aimin Tang; Keith A Wilson; Minchun Chen; Helen C Perry; Gwendolyn J Heidecker; Daniel C Freed; Anthony Carella; Kara S Punt; Kara J Sykes; Lingyi Huang; Virginia I Ausensi; Margaret Bachinsky; Usha Sadasivan-Nair; David I Watkins; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; M Piatak; T Parks; L Li; R Kiser; V Coalter; B Fisher; B M Flynn; S Czajak; V M Hirsch; K A Reimann; J E Schmitz; J Ghrayeb; N Bischofberger; M A Nowak; R C Desrosiers; D Wodarz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL.

Authors:  Otto O Yang; Phuong T Nguyen Sarkis; Alicja Trocha; Spyros A Kalams; R Paul Johnson; Bruce D Walker
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

9.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Authors:  L Jean Patterson; Nina Malkevitch; David Venzon; Joel Pinczewski; Victor Raúl Gómez-Román; Liqun Wang; V S Kalyanaraman; Phillip D Markham; Frank A Robey; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  148 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

2.  Simian immunodeficiency virus SIVmac239Deltanef vaccination elicits different Tat28-35SL8-specific CD8+ T-cell clonotypes compared to a DNA prime/adenovirus type 5 boost regimen in rhesus macaques.

Authors:  Benjamin J Burwitz; Zachary Ende; Benjamin Sudolcan; Matthew R Reynolds; Justin M Greene; Benjamin N Bimber; Jorge R Almeida; Monica Kurniawan; Vanessa Venturi; Emma Gostick; Roger W Wiseman; Daniel C Douek; David A Price; David H O'Connor
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques.

Authors:  Hiroshi Ishii; Miki Kawada; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Saori Matsuoka; Teiichiro Shiino; Akiko Takeda; Makoto Inoue; Akihiro Iida; Hiroto Hara; Tsugumine Shu; Mamoru Hasegawa; Taeko K Naruse; Akinori Kimura; Masafumi Takiguchi; Tetsuro Matano
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Pyrosequencing reveals restricted patterns of CD8+ T cell escape-associated compensatory mutations in simian immunodeficiency virus.

Authors:  Benjamin J Burwitz; Jonah B Sacha; Jason S Reed; Laura P Newman; Francesca A Norante; Benjamin N Bimber; Nancy A Wilson; David I Watkins; David H O'Connor
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

Review 5.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

7.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

8.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

9.  The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers.

Authors:  Juan P Giraldo-Vela; Richard Rudersdorf; Chungwon Chung; Ying Qi; Lyle T Wallace; Benjamin Bimber; Gretta J Borchardt; Debra L Fisk; Chrystal E Glidden; John T Loffredo; Shari M Piaskowski; Jessica R Furlott; Juan P Morales-Martinez; Nancy A Wilson; William M Rehrauer; Jeffrey D Lifson; Mary Carrington; David I Watkins
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

10.  Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.

Authors:  Bapi Pahar; Andrew A Lackner; Michael Piatak; Jeffrey D Lifson; Xiaolei Wang; Arpita Das; Binhua Ling; David C Montefiori; Ronald S Veazey
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.